Genetic variants and the risk of Crohn’s disease: what does it mean for future disease management?

Bibliography

• KIRSNER JB, SPENCER JA: Family occurences of ulcerative colitis, regional enteritis, and ileocolitis. Ann. Intern. Med. (1963) 59:133-244.
   PubMed Web of Science ®Google Scholar
• ORHOLM M, ISELIUS L, SORENSEN TI, MUNKHOLM P, LANGHOLZ E, BINDER V: Investigation of inheritance of chronic inflammatory bowel diseases by complex segregation analysis. Br. Med. J. (1993) 306:20-24.
   PubMedGoogle Scholar
• AHMAD T, TAMBOLI CP, JEWELL D, COLOMBEL JF: Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology (2004) 126:1533-1549.
   PubMed Web of Science ®Google Scholar
• HUGOT JP, LAURENT-PUIG P, GOWER-ROUSSEAU C et al.: Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 29:821-823.
   Google Scholar
• CURRAN ME, LAU KF, HAMPE J et al.: Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology (1998) 115:1066-1071.
   PubMed Web of Science ®Google Scholar
• BRANT SR, FU Y, FIELDS CT et al.: American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology (1998) 115:1056-1061.
   PubMed Web of Science ®Google Scholar
• CAVANAUGH J; IBD INTERNATIONAL GENETICS CONSORTIUM: International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16. Am. J. Hum. Genet. (2001) 68:1165-1171.
   PubMed Web of Science ®Google Scholar
• HUGOT JP, CHAMAILLARD M, ZOUALI H et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 31:599-603.
   Google Scholar
• OGURA Y, BONEN DK, INOHARA N et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 31:603-606.
   Google Scholar
• HAMPE J, CUTHBERT A, CROUCHER PJ et al.: Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet (2001) 16:1925-1928.
   Google Scholar
• LESAGE S, ZOUALI H, CEZARD JP et al.: CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am. J. Hum. Genet. (2002) 70:845-857.
   PubMed Web of Science ®Google Scholar
• SCHNITZLER F, BRAND S, STAUDINGER T et al.: Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease. Immunogenetics (2006) 58(2-3):99-106.
   PubMed Web of Science ®Google Scholar
• ECONOMOU M, TRIKALINOS TA, LOIZOU KT, TSIANOS EV, IOANNIDIS JP: Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am. J. Gastroenterol. (2004) 99:2393-2404.
   PubMed Web of Science ®Google Scholar
• BONEN DK, OGURA Y, NICOLAE DL et al.: Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology (2003) 124:140-146.
   PubMed Web of Science ®Google Scholar
• INOUE N, TAMURA K, KINOUCHI Y et al.: Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology (2002) 123:86-91.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI K, TAKAZOE M, TANAKA T, KAZUMORI T, NAKAMURA Y: Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J. Hum. Genet. (2002) 47:469-472.
   PubMed Web of Science ®Google Scholar
• SUGIMURA M, KINOUCHI Y, TAKAHASHI S et al.: CARD15/NOD2 mutational analysis in Japanese patients with Crohn's disease. Clin. Genet. (2003) 63:160-162.
   PubMed Web of Science ®Google Scholar
• CROUCHER PJ, MASCHERETTI S, HAMPE J et al.: Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur. J. Hum. Genet. (2003) 11:6-16.
   PubMed Web of Science ®Google Scholar
• LEONG RW, ARMUZZI A, AHMAD T et al.: NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment. Pharmacol. Ther. (2003) 17:1465-1470.
   PubMed Web of Science ®Google Scholar
• MEDICI V, MASCHERETTI S, CROUCHER PJ et al.: Extreme heterogeneity in CARD15 and DLG5 Crohn disease-associated polymorphisms between German and Norwegian populations. Eur. J. Hum. Genet. (2006) 14:459-468.
   PubMed Web of Science ®Google Scholar
• OGURA Y, INOHARA N, BENITO A, CHEN FF, YAMAOKA S, NUNEZ G: Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J. Biol. Chem. (2001) 276:4812-4818.
   PubMed Web of Science ®Google Scholar
• HISAMATSU T, SUZUKI M, REINECKER HC, NADEAU WJ, MCCORMICK BA, PODOLSKY DK: CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology (2003) 124:993-1000.
   PubMed Web of Science ®Google Scholar
• ROSENSTIEL P, FANTINI M, BRAUTIGAM K et al.: TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology (2003) 124:1001-1009.
   PubMed Web of Science ®Google Scholar
• LALA S, OGURA Y, OSBORNE C et al.: Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology (2003) 125:47-57.
   PubMed Web of Science ®Google Scholar
• INOHARA N, OGURA Y, FONTALBA A et al.: Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. (2003) 278:5509-5512.
   PubMed Web of Science ®Google Scholar
• GIRARDIN SE, BONECA IG, VIALA J et al.: Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. (2003) 278:8869-8872.
   PubMed Web of Science ®Google Scholar
• VAVRICKA SR, MUSCH MW, CHANG JE et al.: hPepT1 transports muramyl dipeptide, activating NF-κB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology (2004) 127:1401-1409.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI K, INOHARA N, HERNANDEZ LD et al.: RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature (2002) 416:194-199.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, NIKOLAUS S, HAMPE J: Activation of nuclear factor κB inflammatory bowel disease. Gut (1998) 42:477-484.
   PubMed Web of Science ®Google Scholar
• ECKMANN L, KARIN M: NOD2 and Crohn's disease: loss or gain of function? Immunity (2005) 22:661-667.
   PubMed Web of Science ®Google Scholar
• WATANABE T, KITANI A, MURRAY PJ, STROBER W: NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. (2004) 5:800-808.
   PubMed Web of Science ®Google Scholar
• NETEA MG, FERWERDA G, DE JONG DJ et al.: Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J. Immunol. (2005) 174:6518-6523.
   PubMed Web of Science ®Google Scholar
• MAEDA S, HSU LC, LIU H et al.: Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science (2005) 307:734-738.
   PubMed Web of Science ®Google Scholar
• NETEA MG, FERWERDA G, DE JONG DJ, GIRARDIN SE, KULLBERG BJ, VAN DER MEER JW: NOD2 3020insC mutation and the pathogenesis of Crohn's disease: impaired IL-1β production points to a loss-of-function phenotype. Neth. J. Med. (2005) 63:305-308.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI KS, CHAMAILLARD M, OGURA Y et al.: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science (2005) 307:731-734.
   PubMed Web of Science ®Google Scholar
• WEHKAMP J, HARDER J, WEICHENTHAL M et al.: NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut (2004) 53:1658-1664.
   PubMed Web of Science ®Google Scholar
• HAMPE J, FRENZEL H, MIRZA MM et al.: Evidence for a NOD2-independent susceptibility locus for inflammatory bowel disease on chromosome 16p. Proc. Natl. Acad. Sci. USA. (2002) 99:321-326.
   PubMedGoogle Scholar
• VAN HEEL DA, FISHER SA, KIRBY A et al.: Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum. Mol. Genet. (2004) 13:763-770.
   PubMed Web of Science ®Google Scholar
• PELTEKOVA VD, WINTLE RF, RUBIN LA et al.: Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat. Genet. (2004) 36:471-475.
   PubMed Web of Science ®Google Scholar
• RIOUX JD, DALY MJ, SILVERBERG MS et al.: Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet. (2001) 29:223-228.
   PubMed Web of Science ®Google Scholar
• REINHARD C, RIOUX JD: Role of the IBD5 susceptibility locus in the inflammatory bowel diseases. Inflamm. Bowel Dis. (2006) 12:227-238.
   PubMedGoogle Scholar
• GRUNDEMANN D, HARLFINGER S, GOLZ S et al.: Discovery of the ergothioneine transporter. Proc. Natl. Acad. Sci. USA. (2005) 102:5256-5261.
   PubMed Web of Science ®Google Scholar
• TAUBERT D, GRIMBERG G, JUNG N, RUBBERT A, SCHOMIG E: Functional role of the 503F variant of the organic cation transporter OCTN1 in Crohn's disease. Gut (2005) 54:1505-1506.
   PubMedGoogle Scholar
• TÖRÖK HP, GLAS J, TONENCHI L et al.: Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut (2005) 54:1421-1427.
   PubMed Web of Science ®Google Scholar
• NOBLE CL, NIMMO ER, DRUMMOND H et al.: The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology (2005) 129:1854-1864.
   PubMed Web of Science ®Google Scholar
• MARTINEZ A, DEL CARMEN MARTIN M, MENDOZA JL et al.: Association of the organic cation transporter OCTN genes with Crohn's disease in the Spanish population. Eur. J. Hum. Genet. (2006) 14:222-226.
   PubMedGoogle Scholar
• HAMPE J, SCHREIBER S, SHAW SH et al.: A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am. J. Hum. Genet. (1999) 64:808-816.
   PubMed Web of Science ®Google Scholar
• STOLL M, CORNELIUSSEN B, COSTELLO CM et al.: Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat. Genet. (2004) 36:476-480.
   PubMed Web of Science ®Google Scholar
• DALY MJ, PEARCE AV, FARWELL L et al.: Association of DLG5 R30Q variant with inflammatory bowel disease. Eur. J. Hum. Genet. (2005) 13:835-839.
   PubMed Web of Science ®Google Scholar
• NOBLE CL, NIMMO ER, DRUMMOND H, SMITH L, ARNOTT ID, SATSANGI J: DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population. Gut (2005) 54:1416-1420.
   PubMed Web of Science ®Google Scholar
• VERMEIRE S, PIERIK M, HLAVATY T et al.: Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. Gastroenterology (2005) 129:1845-1853.
   PubMed Web of Science ®Google Scholar
• FRIEDRICHS F, BRESCIANINI S, ANNESE V et al.: Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Hum. Genet. (2006) 119:305-311.
   PubMed Web of Science ®Google Scholar
• PIERIK M, YANG H, BARMADA MM et al.: The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction. Inflamm. Bowel. Dis. (2005) 11:1-7.
   PubMed Web of Science ®Google Scholar
• HAMPE J, SHAW SH, SAIZ R et al.: Linkage of inflammatory bowel disease to human chromosome 6p. Am. J. Hum. Genet. (1999) 65:1647-1655.
   PubMed Web of Science ®Google Scholar
• NOMURA E, KINOUCHI Y, NEGORO K et al.: Mapping of a disease susceptibility locus in chromosome 6p in Japanese patients with ulcerative colitis. Genes Immun. (2004) 5:477-483.
   PubMedGoogle Scholar
• YAP LM, AHMAD T, JEWELL DP: The contribution of HLA genes to IBD susceptibility and phenotype. Best. Pract. Res. Clin. Gastroenterol. (2004) 18:577-596.
   PubMed Web of Science ®Google Scholar
• STOKKERS PC, REITSMA PH, TYTGAT GN, VAN DEVENTER SJ: HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut (1999) 45:395-401.
   PubMed Web of Science ®Google Scholar
• GLAS J, MARTIN K, BRUNNLER G et al.: MICA, MICB and C1_4_1 polymorphism in Crohn's disease and ulcerative colitis. Tissue Antigens (2001) 58:243-249.
   PubMedGoogle Scholar
• VAN HEEL DA, UDALOVA IA, DE SILVA AP et al.: Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-κ)B transcription factors. Hum. Mol. Genet. (2002) 18:1281-1289.
   Google Scholar
• YANG H, VORA DK, TARGAN SR, TOYODA H, BEAUDET AL, ROTTER JI: Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterology (1995) 109:440-448.
   PubMed Web of Science ®Google Scholar
• BRAUN C, ZAHN R, MARTIN K, ALBERT E, FOLWACZNY C. Polymorphisms of the ICAM-1 gene are associated with inflammatory bowel disease, regardless of the p-ANCA status. Clin. Immunol. (2001) 101:357-360.
   PubMed Web of Science ®Google Scholar
• LOW JH, WILLIAMS FA, YANG X et al.: Inflammatory bowel disease is linked to 19p13 and associated with ICAM-1. Inflamm. Bowel Dis. (2004) 10:173-181.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI K, MCGOVERN D, RAGOUSSIS J et al.: Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum. Mol. Genet. (2005) 14:3499-3506.
   PubMed Web of Science ®Google Scholar
• DRING MM, GOULDING CA, TRIMBLE VI et al.: The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology (2006) 130:341-348.
   PubMed Web of Science ®Google Scholar
• FRANCHIMONT D, VERMEIRE S, EL HOUSNI H et al.: Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut (2004) 53:987-992.
   PubMed Web of Science ®Google Scholar
• TÖRÖK HP, GLAS J, TONENCHI L, MUSSACK T, FOLWACZNY C: Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin. Immunol. (2004) 112:85-91.
   PubMed Web of Science ®Google Scholar
• BRAND S, STAUDINGER T, SCHNITZLER F et al.: The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm. Bowel Dis. (2005) 11:645-652.
   PubMed Web of Science ®Google Scholar
• TÖRÖK HP, GLAS J, TONENCHI L, BRUENNLER G, FOLWACZNY M, FOLWACZNY C: Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology (2004) 127:365-366.
   PubMed Web of Science ®Google Scholar
• RACHMILEWITZ D, KATAKURA K, KARMELI F et al.: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology (2004) 126:520-528.
   PubMed Web of Science ®Google Scholar
• OBERMEIER F, DUNGER N, STRAUCH UG et al.: Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis. Clin. Exp. Immunol. (2003) 134:217-224.
   PubMed Web of Science ®Google Scholar
• PIERIK M, JOOSSENS S, VAN STEEN K et al.: Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm. Bowel Dis. (2006) 12:1-8.
   PubMed Web of Science ®Google Scholar
• ZOUALI H, LESAGE S, MERLIN F et al.: CARD4/NOD1 is not involved in inflammatory bowel disease. Gut (2003) 52:71-74.
   PubMed Web of Science ®Google Scholar
• MCGOVERN DP, HYSI P, AHMAD T et al.: Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum. Mol. Genet. (2005) 14:1245-1250.
   PubMed Web of Science ®Google Scholar
• BAYLESS TM, TOKAYER AZ, POLITO JM II, QUASKEY SA, MELLITS ED, HARRIS ML: Crohn's disease: concordance for site and clinical type in affected family members – potential hereditary influences. Gastroenterology (1996) 111:573-579.
   PubMed Web of Science ®Google Scholar
• AHMAD T, ARMUZZI A, BUNCE M et al. : The molecular classification of the clinical manifestations of Crohn’s disease. Gastroenterology (2002) 122:854-866.
   PubMed Web of Science ®Google Scholar
• RADLMAYR M, TÖRÖK HP, MARTIN K, FOLWACZNY C: The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology (2002) 122:2091-2092.
   PubMed Web of Science ®Google Scholar
• BRANT SR, PICCO MF, ACHKAR JP et al.: Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm. Bowel Dis. (2003) 9:281-289.
   PubMed Web of Science ®Google Scholar
• LOUIS E, MICHEL V, HUGOT JP et al.: Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut (2003) 52:552-557.
   PubMed Web of Science ®Google Scholar
• MARDINI HE, GREGORY KJ, NASSER M et al.: Gastroduodenal Crohn's disease is associated with NOD2/CARD15 gene polymorphisms, particularly L1007P homozygosity. Dig. Dis. Sci. (2005) 50:2316-2322.
   PubMed Web of Science ®Google Scholar
• HOLLER E, ROGLER G, HERFARTH H et al.: Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood (2004) 104:889-894.
   PubMed Web of Science ®Google Scholar
• AHMAD T, ARMUZZI A, NEVILLE M et al.: The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens (2003) 62:527-535.
   PubMedGoogle Scholar
• SILVERBERG MS, MIREA L, BULL SB et al.: A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflamm. Bowel Dis. (2003) 9:1-9.
   PubMed Web of Science ®Google Scholar
• ANNESE V, PIEPOLI A, LATIANO A et al.: HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis. Colon. Rectum (2005) 48:57-64.
   PubMed Web of Science ®Google Scholar
• LOUIS E, BELAICHE J: Genetics of Crohn's disease behaviour. Acta. Gastroenterol. Belg. (2000) 63:377-379.
   PubMedGoogle Scholar
• LEVINE A, SHAMIR R, WINE E et al.: TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease. Am. J. Gastroenterol. (2005) 100:1598-1604.
   PubMedGoogle Scholar
• MASCHERETTI S, CROUCHER PJ, SCHREIBER S: Pharmacogenetics of inflammatory bowel disease. Best. Pract. Res. Clin. Gastroenterol. (2004) 18:597-609.
   PubMedGoogle Scholar
• WEINSHILBOUM RM, SLADEK SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. (1980) 32:651-662.
   PubMed Web of Science ®Google Scholar
• YATES CR, KRYNETSKI EY, LOENNECHEN T et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. (1997) 126:608-614.
   PubMed Web of Science ®Google Scholar
• KRYNETSKI EY, SCHUETZ JD, GALPIN AJ, PUI CH, RELLING MV, EVANS WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl. Acad. Sci. USA. (1995) 92:949-953.
   PubMed Web of Science ®Google Scholar
• TAI HL, KRYNETSKI EY, YATES CR et al.: Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. (1996) 58:694-702.
   PubMed Web of Science ®Google Scholar
• TAI HL, KRYNETSKI EY, SCHUETZ EG, YANISHEVSKI Y, EVANS WE: Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. USA (1997) 94:6444-6449.
   PubMed Web of Science ®Google Scholar
• WEINSHILBOUM RM, SLADEK SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. (1980) 32:651-662.
   PubMed Web of Science ®Google Scholar
• COLOMBEL JF, FERRARI N, DEBUYSERE H et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology (2000) 118:1025-1030.
   PubMed Web of Science ®Google Scholar
• WINTER J, WALKER A, SHAPIRO D et al.: Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. (2004) 20:593-599.
   PubMed Web of Science ®Google Scholar
• DUBINSKY MC, REYES E, OFMAN J, CHIOU CF, WADE S, SANDBORN WJ: A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. (2005) 100:2239-2247.
   PubMed Web of Science ®Google Scholar
• DUBINSKY MC, YANG H, HASSARD PV et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 122:904-915.
   PubMed Web of Science ®Google Scholar
• HONDA M, ORII F, AYABE T et al.: Expression of glucocorticoid receptor β in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology (2000) 118:859-866.
   PubMed Web of Science ®Google Scholar
• DILGER K, SCHWAB M, FROMM MF: Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm. Bowel Dis. (2004) 10:578-583.
   PubMed Web of Science ®Google Scholar
• SCHWAB M, SCHAEFFELER E, MARX C et al.: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 124:26-33.
   PubMed Web of Science ®Google Scholar
• HO GT, NIMMO ER, TENESA A et al.: Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology (2005) 128:288-296.
   PubMed Web of Science ®Google Scholar
• CROUCHER PJ, MASCHERETTI S, FOELSCH UR, HAMPE J, SCHREIBER S: Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterology (2003) 125:1919-1920.
   PubMed Web of Science ®Google Scholar
• GLAS J, TÖRÖK HP, SCHIEMANN U, FOLWACZNY C: MDR1 gene polymorphism in ulcerative colitis. Gastroenterology (2004) 126:367.
   PubMedGoogle Scholar
• BRANT SR, PANHUYSEN CI, NICOLAE D et al.: MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet. (2003) 73:1282-1292.
   PubMed Web of Science ®Google Scholar
• POTOCNIK U, FERKOLJ I, GLAVAC D, DEAN M: Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes. Immun. (2004) 5:530-539.
   PubMed Web of Science ®Google Scholar
• HO GT, SORANZO N, NIMMO ER, TENESA A, GOLDSTEIN DB, SATSANGI J: ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum. Mol. Genet. (2006) 15:797-805.
   PubMed Web of Science ®Google Scholar
• FARRELL RJ, MURPHY A, LONG A et al.: High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology (2000) 118:279-288.
   PubMed Web of Science ®Google Scholar
• PALMIERI O, LATIANO A, VALVANO R et al.: Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment. Pharmacol. Ther. (2005) 22:1129-1138.
   PubMed Web of Science ®Google Scholar
• HERESBACH D, ALIZADEH M, BRETAGNE JF et al.: TAP gene transporter polymorphism in inflammatory bowel diseases. Scand. J. Gastroenterol. (1997) 32:1022-1027.
   PubMed Web of Science ®Google Scholar
• GELBMANN CM, ROGLER G, GIEREND M, GROSS V, SCHOLMERICH J, ANDUS T: Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease. Eur. J. Gastroenterol. Hepatol. (2001) 13:1431-1437.
   PubMedGoogle Scholar
• LOUIS E, VERMEIRE S, RUTGEERTS P et al.: A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. (2002) 37:818-824.
   PubMed Web of Science ®Google Scholar
• MASCHERETTI S, HAMPE J, KUHBACHER T et al.: Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J. (2002) 2:127-136.
   PubMedGoogle Scholar
• PIERIK M, VERMEIRE S, STEEN KV et al.: Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment. Pharmacol. Ther. (2004) 20:303-310.
   PubMed Web of Science ®Google Scholar
• VERMEIRE S, LOUIS E, RUTGEERTS P et al.: NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology (2002) 123:106-111.
   PubMed Web of Science ®Google Scholar
• MASCHERETTI S, HAMPE J, CROUCHER PJ et al.: Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics (2002) 12:509-515.
   PubMedGoogle Scholar
• LOUIS E, EL GHOUL Z, VERMEIRE S et al.: Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. (2004) 19:511-519.
   PubMed Web of Science ®Google Scholar
• WILLOT S, VERMEIRE S, OHRESSER M et al.: No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet. Genomics (2006) 16:37-42.
   PubMed Web of Science ®Google Scholar
• HLAVATY T, PIERIK M, HENCKAERTS L et al.: Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment. Pharmacol. Ther. (2005) 22:613-626.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JR, JEWELL DP: Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm. Bowel. Dis. (2005) 11:56-61.
   PubMedGoogle Scholar